Project Grant R41CA287488
Award Date
9/3/24
Completion Date
8/31/25
Dollars Obligated
$400K
Federal Agency
National Cancer Institute
Awardee
Immunoblue, LLC (ZGGMBZWMF5H3)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Washington, DC 20052, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The University of Texas M.D. Anderson Cancer Center provides $432,134.00 in funding to establish a radiotheranostic approach for treating glioblastoma (GBM), a highly aggressive brain cancer, by targeting the IL13RA2 protein expressed on cancer cells. The research aims to develop human monoclonal antibodies that bind to IL13RA2 with high affinity and specificity, and evaluate the...
The National Cancer Institute (NCI) awarded a $1,200,000 Project Grant under CFDA 93.395 - Cancer Treatment Research to Creative Biotherapeutics LLC, a biotechnology research firm, to develop a novel biologic therapy to eradicate brain cancer and brain metastases. The funded research aims to target the extracellular glucose-regulated protein 78 (eGRP78) expressed on the surface of drug-resistant tumor cells, in order to induce apoptosis, eliminate drug and immune resistance, and reduce the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The General Hospital Corporation, doing business as Massachusetts General Hospital, to conduct a Phase I clinical trial evaluating the safety and feasibility of CARV3.TEAM-E cells for the treatment of primary or recurrent glioblastoma (GBM), a deadly brain tumor. The CARV3.TEAM-E cells are genetically engineered chimeric antigen receptor (CAR) T cells that target the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) totaling $949,312 provides funding for the University of Florida to develop a "next-generation" precision adoptive cell therapy (ACT) approach for the treatment of pediatric high-grade gliomas. The project aims to utilize patient-specific antigen profiling, a novel gene enrichment strategy, and a selective expansion platform to generate enriched, polyclonal tumor-reactive T...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research Grant Program (CFDA 93.395), awarded a $398,997 Project Grant to Immunogenik, Inc. in Gainesville, Florida. The grant supports the development and evaluation of a "3-in-1" Chimeric Antigen Receptor (CAR) T-cell therapy to enhance cancer treatment. The project aims to overcome limitations of current cancer therapies by targeting tumor-associated myeloid cells, which play a key role in cancer...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), is providing $748,337 to Pyrojas Inc. to develop an innovative "Pyrotimer" CAR-T cell therapy. The goal is to create a more potent and persistent CAR-T cell treatment that can overcome the immunosuppressive tumor microenvironment, particularly by inhibiting transforming growth factor-beta (TGF-β). The research plan involves extensive in vitro and in vivo...
The National Cancer Institute (NCI) awarded a $399,214 Project Grant under CFDA 93.395 - Cancer Treatment Research to Proton Bio, Inc., a minority-owned business located in Baltimore, Maryland. The grant supports a 12-month project to develop and evaluate a novel therapy targeting the proton-sensing receptor GPR68 as a potential treatment for glioblastoma (GBM), the most common and aggressive form of adult brain cancer. The project will focus on three key objectives: 1) define the in vitro...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $163,640 to the University of Virginia to develop novel non-viral gene delivery platforms for the treatment of glioblastoma, an aggressive brain cancer. The research aims to improve the therapeutic accumulation and delivery of gene therapies by leveraging brain-penetrating nanoparticles and focused ultrasound technology. Key objectives include investigating the tumor-targeting and...